Skip to content

Fatigue in MS: From Invisible to Measurable

Fatigue in MS: From Invisible to Measurable

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07182903
Acronym
FIMS
Enrollment
34
Registered
2025-09-19
Start date
2025-10-27
Completion date
2026-04-02
Last updated
2026-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Keywords

multiple sclerosis, fatigue, cytotoxic CD4 T cells

Brief summary

Fatigue is one of the most common and burdensome symptoms of MS, but its precise cause remains unknown, and an effective treatment is lacking. Previous research has shown that the progression of MS is associated with a higher presence of a specific type of T-cell, the cytotoxic CD4+ T-cells, which play a role in the immune system. The aim of this study is to investigate whether these cells can also be linked to fatigue in people with MS.

Detailed description

Forty individuals with MS will be asked to complete questionnaires about fatigue and perform motor tasks. Additionally, blood samples will be taken to measure the levels of cytotoxic CD4+ T-cells. These values will then be correlated with fatigue scores and performance on the motor tasks. Scores from the fatigue questionnaires and decline in amplitude and frequency from the performance fatiguability test will be correlated to the level of CD4 CTLs from the blood samples. Secondary study parameters include muscle activation patterns measured by EMG, distance walked on 6MWT and voluntary muscle activation.

Interventions

None listed

Sponsors

University Medical Center Groningen
Lead SponsorOTHER
UHasselt
CollaboratorUNKNOWN

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of relapsing remittion, primary progressive or secondary progressive MS * Age: 18-60 years * Ability to perform the foot-tapping task * Ability to walk at least 20 meters (with or without walking aid)

Exclusion criteria

* Dimethyl fumarate, fingolimod or alemtuzumab treatment, since these medications have a strong influence on the immune system As a result of these treatments, there are few to no immune cells circulating in the blood, meaning we cannot find our population of interest in the blood. * Change in medication 6 weeks before the start of the study (including medication not related to MS) - MS relapse within 6 weeks of the start of the study * Had an infection in the last month - Received a vaccination in the last 14 days - Pregnant or pregnancy in the last 6 months * Having a psychiatric disorder * Having a neurological disorder other than MS * Having cognitive or communicative problems that makes it hard to follow instructions

Design outcomes

Primary

MeasureTime frameDescription
Correlation between percentage of cytotoxic CD4+ T cells and FSS scoreDay 1Bivariate correlations will be calculated between the percentage of cytotoxic CD4+ T cells and fatigue, measured with Fatigue Severity Scale (FSS).
Correlation between percentage of cytotoxic CD4+ T cells and MFIS scoreDay 1Bivariate correlations will be calculated between the percentage of cytotoxic CD4+ T cells and fatigue, measured with Modified Fatigue Impact Scale (MFIS).
Correlation between percentage of cytotoxic CD4+ T cells and foot-tapping frequency decreaseDay 1Bivariate correlations will be calculated between the percentage of cytotoxic CD4+ T cells and fatigability, measured as the decrease in frequency from the first 10 seconds of the task to the last 10 seconds of the task.
Correlation between percentage of cytotoxic CD4+ T cells and foot-tapping amplitude decreaseDay 1Bivariate correlations will be calculated between the percentage of cytotoxic CD4+ T cells and fatigability, measured as the decrease in amplitude from the first 10 seconds of the task to the last 10 seconds of the task.

Secondary

MeasureTime frameDescription
Changes in muscle activation during 6MWTDay 1Comparison of the root-mean-square (RMS) of the EMG signal at the beginning of the task and the end of the task.
Changes in muscle activation during foot tapping taskDay 1Comparison of the root-mean-square (RMS) of the EMG signal at the beginning (first 10 seconds) of the task and the end (last 10 seconds) of the task.
Correlation changes in walking distance between the first and last minute of the 6MWT and CD4+ CTLsDay 1Changes in distance between the first minute and the last minute of the 6MWT are measured to assess walking fatigability and will be correlated with the percentage of CD4+ CTLs in the blood.
Correlation percentage voluntary muscle activation and CD4+ CTLsDay 1The correlation is calculated between the percentage of CD4+ CTLs in the blood and the percentage of voluntary activation (1 - superimposed twitch/initial-doublet) x 100%).

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 21, 2026